[Measuring quality of life. A new general and a new tumor specific formulary for evaluation and planning].
The generic measure, SF-36, was developed in the US. It covers both functioning and well-being and has proved suitable for clinical outcomes research, patient monitoring and health care planning. To protect the forms and scoring algorithms of the SF-36 and ensure comparability across studies and countries the copyright was placed with Medical Outcomes Trust, a non-profit making organization. Researchers are granted permission through a user agreement procedure. An international team of investigators is developing authorized translations of the SF-36 through the International Quality of Life Assessment (IQOLA) Project, sponsored by Glaxo Research Institute, Research Triangle Park, North Carolina, USA, and Schering-Plough Corporation, Kenilworth, New Jersey, USA. The Swedish test version is currently available on a case-by-case basis at the Health Care Research Unit. The tumor-specific measure, QLQ-C30, was developed and proved reliable in cross-cultural field studies, created by the Quality of Life Study Group within the European Organization for Research and Treatment of Cancer (EORTC). It includes questions on functioning, symptom burden and global quality of life across tumors, supplemented by diagnosis--or therapy-specific additional modules. The instrument is copyrighted and all translations are placed with the Quality of Life Unit at the EORTC Data Center, Brussels. Requests for permission to use the instrument and scoring instructions should be sent to the Center.